Turkish Ministry of Health Grants Nationwide Reimbursement for CytoSorb®


The cost of treatment with CytoSorb® will now be covered by the public sector Turkey

PRINCETON, N.J., August 23, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that the Turkish Ministry of Health has approved national reimbursement for CytoSorb®, which is now a catalog product reimbursed at the State Office of Supply of Turkey (DMO) and can be purchased directly by hospitals and doctors without restrictions.

dr. Christian SteinerExecutive Vice President, Sales and Marketing of CytoSorbents, said, “We greatly appreciate the Turkish Ministry of Health’s recognition of the important role that CytoSorb can play in the management of complex patients who are critically ill or undergoing cardiothoracic surgery. Turkey, an estimated 140,000 patients are treated in the ICU for severe sepsis or septic shock related to an infection, with a high risk of death. It is also estimated that more than 75,000 patients undergo cardiothoracic surgery each year, many of whom are medical tourists treated in private hospitals. Additionally, there are many other critically ill patients with other life-threatening conditions such as acute lung or liver failure, trauma, and others where CytoSorb can be used to control life-threatening inflammation and provide organ support. . Now, with reimbursement, more patients will have access to our breakthrough CytoSorb treatment that adds a new dimension to blood purification. »

Dr. Steiner praised the strategic collaboration with the new distribution partner, Bıçakcılar Medical Devices. “Our partnership with Bıçakcılar was instrumental in obtaining national reimbursement and the inclusion of CytoSorb® in the DMO’s healthcare catalog. We look forward to working more closely with them to leverage our new refund and expand the Turkish market for our products.

Bıçakcılar Medical Devices is the leading manufacturer of disposable medical products and OR solutions in Turkey. The company was established in 1959. Over the years, the Bıçakcılar brand has gained wide acceptance and established a tradition of continued reliability and customer satisfaction.

dr. Souheil El-HakimCEO of Bıçakcılar, highlighted the important alignment of both companies on patient-centric solutions that are essential to improve clinical outcomes for critically ill patients in Turkey and beyond. “We believe that everyone deserves affordable and effective healthcare. In critical care medicine in particular, we are able to deliver the most effective therapies using our extensive production facilities. At the same time, we work to have a direct impact on healthcare. With CytoSorbents, we have found one of the most innovative partners to help us achieve this goal, giving us the opportunity to bring our approach even more to life.

Turkey provides universal health care to approximately 95% of the 84 million citizens of the country, which is comparable in size to Germany. There are more than 1,500 hospitals, of which about 62% are public or university hospitals and 38% are private. Turkey has an extensive network of intensive care units, with one of the highest numbers of intensive care beds per 100,000 population among developed countries at around 46, compared to 29 in the United States and 39 in Germanyfor example. Turkey is also a medical tourism hub in the region, attracting 1.7 million patients from outside Turkey each year, especially for surgical procedures such as cardiovascular, thoracic, plastic, orthopedic, and others.

About Bıçakcılar Medical

Bıçakcılar Medical is a 60-year-old company that has created many “firsts” in Turkey where he was born. Over the years, expanding globally, Bıçakcılar Medical has helped save lives around the world by providing crucial healthcare products. From medical consumables to OR Solutions, it stands out with two unique attributes: quality control with zero tolerance for errors and after-sales service by its own experts, adding exceptional durability to its medical equipment. The focus on the ‘patient’ is just one of the reasons many of its international and domestic customers have partnered with the company for over 20 years. With more than 800 employees and numerous business partners, Bıçakcılar serves its customers by manufacturing and supplying innovative, reliable and environmentally friendly medical devices. Bıçakcılar is committed to ensuring that everything it does benefits society and the environment while helping to save lives.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation is a leader in treating life-threatening conditions in critical care and cardiac surgery through blood purification. Its flagship product, CytoSorb®, is approved in the European Union and marketed in over 70 countries worldwide. It is an extracorporeal cytokine adsorber designed to reduce “cytokine storm” or “cytokine release syndrome” which occurs in common serious illnesses and can lead to massive inflammation, organ failure and death of the patient. In these diseases, the risk of death can be extremely high and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to eliminate inflammatory mediators that can lead to postoperative complications, including multiple organ failure. From June 30, 2022, more than 179,000 CytoSorb devices have been used cumulatively worldwide. CytoSorb was originally launched in the European Union under CE marking as the first extracorporeal cytokine adsorber. Additional CE mark extensions have been granted for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and for the removal of ticagrelor and rivaroxaban during cardiothoracic surgery . CytoSorb also received emergency approval from the FDA in United States for use in critically ill adult COVID-19 patients with impending or confirmed respiratory failure. The DrugSorb™-ATR Antithrombotic Removal System, based on the same polymer technology as CytoSorb, also received FDA Breakthrough Device Designation for removing ticagrelor and FDA Breakthrough Device Designation for removing direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during emergency cardiothoracic procedures. The company initiated two pivotal FDA-cleared studies to support the marketing approval of DrugSorb-ATR in the United States. The first is the randomized, controlled STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) study of 120 patients at 30 centers to assess whether intraoperative use of DrugSorb-ATR can reduce the risk of perioperative bleeding in patients on ticagrelor undergoing cardiothoracic surgery. The second study is the STAR‑D (Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized controlled trial of 120 patients at 30 centers evaluating the intraoperative use of DrugSorb-ATR to reduce the risk of perioperative bleeding in patients undergoing cardiothoracic surgery who are taking direct oral anticoagulants, including apixaban and rivaroxaban.

CytoSorbents purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore trapping and surface adsorption. The Company’s technologies have received more than $39.5 million in grants, contracts, and other non-dilutive funding from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the National Heart, Lung, and Blood Institute (NHLBI), US Army, US Air Force, US Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC) and others. The company has numerous marketed and in-development products based on this unique blood purification technology protected by numerous issued U.S. and international patents and registered trademarks, as well as several pending patent applications, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb and others. For more information, please visit the company’s websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.

Forward-looking statements

This press release contains forward-looking statements that fall within the safe harbor of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our plans, objectives, future goals and prospects for our business, expectations regarding the future impact of COVID-19, or the ongoing conflict between Russia and Ukrainerepresentations and assertions, and are not historical facts and are generally identified by the use of words such as “may”, “should”, “could”, “expect”, “plan”, “anticipate” , “believes”, “estimate”, “predict”, “potential”, “continue” and other similar terms, although certain forward-looking statements are worded differently. You should be aware that the forward-looking statements contained in this press release reflect the beliefs and management’s current expectations, but that our actual results, events and performance may differ materially from those contained in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, risks disclosed in our Annual Report on Form 10-K filed with the SEC on March 10, 2022, our quarterly reports on Form 10-Q, and press releases and other shareholder communications that we issue from time to time for the purpose of informing interested parties of the risks and factors that could affect our business. We caution you not to place undue reliance on these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by federal securities laws.

Please click to follow us on Facebook and Twitter

US Company Contact:
Amy Vogel
305 College Road East
Princeton, New Jersey 08540
+1 (732) 329-8885
[email protected]

European company contact:
Josephine Kraus
+49 30 765 84 66 23
[email protected]

US Public Relations:
Eric Kim
Rubenstein Public Relations
[email protected]

European public relations:
Marcus Schult
+49 69 13823 ext. 960
+49 172 4238938
[email protected]

SOURCE CytoSorbents Corporation


Comments are closed.